Skip to content
Clinical Trials – home

ILOPROST TROMETAMOL: A Comprehensive Guide for Patients

1 / 2
trials open to patients / all trials
2+
Countries

In short

Iloprost Trometamol, a medication with diverse applications, is currently being studied in clinical trials for its potential benefits in bone healing and respiratory care. This article delves into two ongoing studies: one investigating its use in improving bone healing for patients with upper arm fractures, and another examining its effects on patients with infectious lung disease requiring mechanical ventilation. These trials aim to assess the safety and efficacy of Iloprost in these specific medical conditions, potentially opening new avenues for treatment.

What is Iloprost Trometamol?

Iloprost Trometamol, also known simply as Iloprost, is a medication that belongs to a class of drugs called prostacyclin analogs. It is a synthetic compound that mimics the effects of a natural substance in your body called prostacyclin. Prostacyclin helps to widen blood vessels and prevent blood clots. Iloprost is primarily used to treat various conditions related to blood circulation and has been the subject of recent clinical trials exploring its potential in other medical applications.

Medical Conditions Treated

Traditionally, Iloprost has been used to treat several medical conditions, including:

  • Pulmonary arterial hypertension: A condition where the blood pressure in the arteries of the lungs is too high
  • Raynaud's phenomenon: A condition that affects blood flow to certain parts of the body, usually the fingers and toes
  • Scleroderma: A group of rare diseases that involve the hardening and tightening of the skin and connective tissues

Recent clinical trials are exploring the use of Iloprost in new areas, such as bone healing and respiratory conditions.

How is Iloprost Administered?

Iloprost is typically administered as an infusion, which means it's given directly into the bloodstream through a vein. The medication comes in the form of a concentrate that is diluted and then given as a solution for infusion. The exact dosage and duration of treatment can vary depending on the condition being treated and the individual patient's needs.

Iloprost for Bone Healing

A recent clinical trial is investigating the use of Iloprost in improving bone healing for patients with upper arm (proximal humeral) fractures. This study, known as the ILOBONE trial, is exploring a new application of Iloprost:

  • The medication is being applied locally at the fracture site during surgery
  • Researchers are studying if this method can promote better bone healing
  • The trial includes patients aged 40 to 80 years old who are undergoing surgery for specific types of upper arm fractures

This research could potentially open up new treatment options for patients with difficult-to-heal bone fractures.

Iloprost in Respiratory Conditions

Another ongoing clinical trial, called COMBAT-ARF, is investigating the use of Iloprost in patients with severe respiratory conditions. This study is focusing on:

  • Patients with infectious pulmonary endotheliopathy, a condition where the infection affects the lining of blood vessels in the lungs
  • Adult patients who require mechanical ventilation (breathing support from a machine)
  • The potential of Iloprost to reduce mortality (death rates) in these severely ill patients

This research aims to determine if Iloprost can improve outcomes for patients with severe lung infections who require intensive care.

Safety Considerations

As with any medication, Iloprost has potential side effects and safety considerations. Some important points to note include:

  • Iloprost may not be suitable for patients with certain heart conditions, including severe coronary heart disease, unstable angina, or recent heart attacks
  • It should be used cautiously in patients with a history of bleeding disorders or recent strokes
  • Pregnant or breastfeeding women should consult their doctor before using Iloprost
  • Some patients may have allergies to Iloprost or its ingredients

Always consult with your healthcare provider about potential risks and benefits before starting any new medication.

Ongoing Research

The clinical trials mentioned in this article are part of ongoing research to expand our understanding of Iloprost's potential uses. These studies are investigating:

  • The safety and effectiveness of Iloprost in new applications, such as bone healing and severe respiratory conditions
  • Different methods of administering the drug, including local application at fracture sites
  • The impact of Iloprost on patient outcomes, including mortality rates and recovery times

As research continues, we may discover new ways that Iloprost can benefit patients with various medical conditions. It's important to note that while these studies are promising, their results are not yet conclusive, and more research may be needed before any new uses for Iloprost are approved.

Questions people often ask

Conditions where Iloprost Trometamol is being studied

Each condition opens its own overview and trial list

Trials with Iloprost Trometamol

Recruiting trials first

See all 2 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).